Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: The role of RELB [Oncotarget., 9, (2018), (7631-7643)] DOI: 10.18632/oncotarget.24146

  • Po Hao Feng
  • , Chih Teng Yu
  • , Kuan Yuan Chen
  • , Ching Shan Luo
  • , Shen Ming Wu
  • , Chien Ying Liu
  • , Lu Wei Kuo
  • , Yao Fei Chan
  • , Tzu Tao Chen
  • , Chih Cheng Chang
  • , Chun Nin Lee
  • , Hsiao Chi Chuang
  • , Chiou Feng Lin
  • , Chia Li Han
  • , Wei Hwa Lee
  • , Kang Yun Lee

Research output: Contribution to journalComment/debate

Abstract

This study was supported by National Science Council (NSC 102-2314-B-038-048) to PHF, Ministry of Science and Technology (MOST 103-2314-B-038 -056 and 104-2314-B-038-070) to PHF, and Taipei Medical University (TMU103- AE1-B31, TMU103-AE2-I01-3, 103TMU-SHH-01-2, 105TMU-SHH-02-2) to PHF.

Original languageEnglish
Pages (from-to)31559
Number of pages1
JournalOncotarget
Volume9
Issue number59
DOIs
StatePublished - 31 07 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© Feng et al.

Fingerprint

Dive into the research topics of 'Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: The role of RELB [Oncotarget., 9, (2018), (7631-7643)] DOI: 10.18632/oncotarget.24146'. Together they form a unique fingerprint.

Cite this